[(2R,3S,4R,5R)-5-(2-氨基-6-氧代-3H-嘌呤-9-基)-4-羟基-2-[[羟基-(羟基-膦酰氧基磷酰)氧基磷酰]氧基甲基]四氢呋喃-3-基]膦酰氢磷酸酯 | 38918-96-6

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷酸
• 中文名称: [(2R,3S,4R,5R)-5-(2-氨基-6-氧代-3H-嘌呤-9-基)-4-羟基-2-[[羟基-(羟基-膦酰氧基磷酰)氧基磷酰]氧基甲基]四氢呋喃-3-基]膦酰氢磷酸酯
• 英文名称: (p)ppGpp
• 英文别名: guanosine pentaphosphate；Guanosine 3'-diphosphate 5'-triphosphate；[(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-4-hydroxy-2-[[hydroxy-[hydroxy(phosphonooxy)phosphoryl]oxyphosphoryl]oxymethyl]oxolan-3-yl] phosphono hydrogen phosphate
• CAS: 38918-96-6
• 化学式: C₁₀H₁₈N₅O₂₀P₅
• 分子量: 683.143
• InChiKey: KCPMACXZAITQAX-UUOKFMHZSA-N

物化性质

• 密度：
  2.94±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -8.8
• 重原子数：
  40
• 可旋转键数：
  12
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  388
• 氢给体数：
  10
• 氢受体数：
  21

文献信息

• Pharmaceutical compositions for treating nitrate-induced tolerance
  申请人：Pfizer Limited

  公开号：EP1022026A2

  公开（公告）日：2000-07-26

  The present invention relates to methods for treating nitrate-induced tolerance in a mammal by administering a nitrate-induced tolerance treating amount of a compound of formulae (I), (II), (III) (IV), (V), (VI), (VII), (VIII), (IX), (XA) or (XB) as defined herein, or the pharmaceutically acceptable salts, prodrugs, polymorphs, hydrates, solvates, active metabolites or stereoisomers thereof. The invention also relates to pharmaceutical compositions for the treatment of nitrate-induced tolerance in a mammal comprising a nitrate-induced tolerance treating amount of a compound of formulae (I), (II), (III) (lV), (V), (VI), (VII), (VIII), (IX), (XA) or (XB) as defined herein, or the pharmaceutically acceptable salts, prodrugs, polymorphs, hydrates, solvates, active metabolites or stereoisomers thereof, and a pharmaceutically acceptable vehicle, diluent or carrier. The invention further relates to methods of preventing nitrate-induced tolerance in a mammal comprising administering a nitrate-induced tolerance preventing amount of a cGMP PDE inhibitor.

  本发明涉及通过施用本文定义的式(I)、(II)、(III)(IV)、(V)、(VI)、(VII)、(VIII)、(IX)、(XA)或(XB)化合物或其药学上可接受的盐、原药、多晶型物、水合物、溶解物、活性代谢物或立体异构体的硝酸盐诱导的耐受性治疗量来治疗哺乳动物的硝酸盐诱导的耐受性的方法。本发明还涉及用于治疗哺乳动物硝酸盐诱导耐受性的药物组合物，其包含硝酸盐诱导耐受性治疗量的式(I)、(II)、(III)(lV)、(V)、(VI)、(VII)、(VIII)、(IX)、(XA)或(XB)，或其药学上可接受的盐、原药、多晶型物、水合物、溶解物、活性代谢物或立体异构体，以及药学上可接受的载体、稀释剂或载体。本发明还涉及防止哺乳动物产生硝酸盐耐受性的方法，包括施用一定量的 cGMP PDE 抑制剂，以防止产生硝酸盐耐受性。
• Method for producing 3-hydroxypropionic acid and other products
  申请人：Cargill, Incorporated

  公开号：US10100342B2

  公开（公告）日：2018-10-16

  This invention relates to metabolically engineered microorganism strains, such as bacterial strains, in which there is an increased utilization of malonyl-CoA for production of a chemical product, which includes 3-hydroxypropionic acid.

  本发明涉及代谢工程微生物菌株，如细菌菌株，在这些菌株中，丙二酰-CoA 在生产化学产品（包括 3-羟基丙酸）方面的利用率有所提高。
• Compositions and methods for diagnosing and treating inflammatory bowel disease and related disorders
  申请人：The Johns Hopkins University

  公开号：US10730916B2

  公开（公告）日：2020-08-04

  The present invention features biomarkers capable of diagnosing inflammatory bowel disease and methods of using such biomarkers to diagnose and selecting treatments for inflammatory bowel diseases.

  本发明的特点是能够诊断炎症性肠病的生物标记物，以及使用这种生物标记物诊断和选择治疗炎症性肠病的方法。
• Polynucleotides and polypeptides, materials incorporating them and methods for using them
  申请人：Glenn Matthew

  公开号：US20050202437A1

  公开（公告）日：2005-09-15

  Novel polynucleotides isolated from Lactobacillus rhamnosus , as well as oligonucleotide probes and primers, genetic constructs comprising the polynucleotides, biological materials, including plants, microorganisms and multicellular organisms incorporating the polynucleotides, polypeptides expressed by the polynucleotides, and methods for using the polynucleotides and polypeptides are disclosed.

  本文公开了从鼠李糖乳杆菌中分离出的新型多核苷酸、寡核苷酸探针和引物、包含该多核苷酸的基因构建体、生物材料（包括包含该多核苷酸的植物、微生物和多细胞生物）、由该多核苷酸表达的多肽以及使用该多核苷酸和多肽的方法。
• INDUCIBLE BACTERIAL EXPRESSION SYSTEM UTILISING SSPA PROMOTER FROM SALMONELLA
  申请人：THE UNIVERSITY OF QUEENSLAND

  公开号：EP1678301A1

  公开（公告）日：2006-07-12